MorphoSys AG (MOR) 2018年年度报告「NASDAQ」.pdf

1、Annual Report 2018annual report2018MorphoSys AGSemmelweisstrasse 782152 PlaneggGermanyPhone:+49-89-89927-0Fax:+49-89-89927-Product PipelineMorphoSyss Product Pipeline(December 31,2018)MOST ADVANCED DEVELOPMENT STAGEPROGRAM/PARTNER INDICATIONTremfya*(guselkumab)/Janssen/J&J Psoriasis Gantenerumab/Roc

2、he Alzheimers disease MOR208/not partnered Hematological malignancies Anetumab ravtansine(BAY94-9343)/Bayer Solid tumors BAY1093884/Bayer Hemophilia BHQ880/Novartis Multiple myeloma Bimagrumab(BYM338)/Novartis Metabolic disease CNTO6785/Janssen/J&J Inflammation Ianalumab(VAY736)/Novartis Inflammatio

3、n MOR103(GSK3196165)/GlaxoSmithKline Inflammation MOR106/Novatis/Galapagos Inflammation MOR202/I-Mab Biopharma*Multiple myeloma NOV-12(MAA868)/Novartis Prevention of thrombosis Setrusumab(BPS804)/Mereo/Novartis Brittle bone syndrome Tesidolumab(LFG316)/Novartis Eye diseases MOST ADVANCED DEVELOPMENT

4、 STAGEPROGRAM/PARTNER INDICATIONUtomilumab(PF-05082566)/Pfizer Cancer Xentuzumab(BI-836845)/BI Solid tumors BAY2287411/Bayer CancerElgemtumab(LJM716)/Novartis CancerMOR107*(LP2-3)/not partnered Not disclosedNOV-7(CLG561)/Novartis Eye diseasesNOV-8/Novartis InflammationNOV-9(LKA651)/Novartis Diabetic

5、 eye diseasesNOV-10(PCA062)/Novartis CancerNOV-11/Novartis Blood disordersNOV-13(HKT288)/Novartis CancerNOV-14/Novartis AsthmaPRV-300(CNTO3157)/ProventionBio InflammationVantictumab(OMP-18R5)/OncoMed Solid tumorsDISCOVERYPRECLINICPHASE 1PHASE 2PHASE 3MARKETDISCOVERYPRECLINICPHASE 1PHASE 2PHASE 3MARK

6、ET12Programs14Programs3Programs*legend:mor program out-licensed mor program partnered discovery program*We still consider Tremfya a phase 3 compound due to ongoing studies in various indications.*For development in China,Hong Kong,Taiwan,Macao.*A phase 1 study in healthy volunteers was completed.MOR